TransEnterix is developing the SurgiBot, the first device to directly compete with Intuitive Surgical. In April of 2014, TransEnterix priced their secondary offering on the worst day the Nasdaq had experienced since 2011, which sent their secondary offering price from the $8.00 range to $4.00. In June of 2014 the company was included in the Russell 2000, which...
